Influence of the CYP2D6*4 polymorphism on dose, switching and discontinuation of antidepressants.
about
The Rotterdam Study: 2010 objectives and design updateTreatment considerations for patients with neuropathic pain and other medical comorbidities.Breast cancer recurrence risk related to concurrent use of SSRI antidepressants and tamoxifenGenetic variability of drug-metabolizing enzymes: the dual impact on psychiatric therapy and regulation of brain function.The Rotterdam Study: 2012 objectives and design update.The burden and management of cytochrome P450 2D6 (CYP2D6)-mediated drug-drug interaction (DDI): co-medication of metoprolol and paroxetine or fluoxetine in the elderly.Role of cytochrome P450 genotype in the steps toward personalized drug therapy.Identifying genetic loci affecting antidepressant drug response in depression using drug-gene interaction models.Variation in the CYP2D6 gene is associated with a lower serum sodium concentration in patients on antidepressants.Adjuvant systemic therapy for older adults with early-stage breast cancer.The intersection of pharmacology, imaging, and genetics in the development of personalized medicine.Fetal serotonin reuptake inhibitor antidepressant exposure: maternal and fetal factors.Do we need pharmacogenetics to personalize antidepressant therapy?Clinical validity of cytochrome P450 metabolism and serotonin gene variants in psychiatric pharmacotherapy.Towards the implementation of CYP2D6 and CYP2C19 genotypes in clinical practice: update and report from a pharmacogenetic service clinic.Polymorphism in CYP2D6 and CYP2C19, members of the cytochrome P450 mixed-function oxidase system, in the metabolism of psychotropic drugs.Association between CYP2D6 Genotypes and the Risk of Antidepressant Discontinuation, Dosage Modification and the Occurrence of Maternal Depression during Pregnancy.Personalizing supportive care in oncology patients using pharmacogenetic-driven treatment pathways.Choosing the safest acute therapy during chronic migraine prophylactic treatment: pharmacokinetic and pharmacodynamic considerations.Pharmacogenetics and Imaging-Pharmacogenetics of Antidepressant Response: Towards Translational Strategies.Influence of CYP2D6 and CYP2C19 gene variants on antidepressant response in obsessive-compulsive disorder.Association between the CYP2D6*4 polymorphism and depression or anxiety in the elderly.Does pharmacogenetic testing for CYP450 2D6 and 2C19 among patients with diagnoses within the schizophrenic spectrum reduce treatment costs?Pharmacokinetics, Safety, and Tolerability of Vortioxetine Following Single- and Multiple-Dose Administration in Healthy Japanese Adults.Pharmacogenetic testing for the guidance of psychiatric treatment: a multicenter retrospective analysis.CYP2D6 ultrarapid metabolism and early dropout from fluoxetine or amitriptyline monotherapy treatment in major depressive patients.Do guidelines recommending pharmacogenetic testing of psychiatric patients affect treatment costs and the use of healthcare services?Value of Supportive Care Pharmacogenomics in Oncology Practice.Pharmacokinetics of venlafaxine extended release 75 mg and desvenlafaxine 50 mg in healthy CYP2D6 extensive and poor metabolizers: a randomized, open-label, two-period, parallel-group, crossover study
P2860
Q24653733-E8A14C26-C162-457C-B669-42953102481AQ33747271-77C34845-B5C3-4716-8704-50933D5F89C0Q33940729-C92955E2-74FD-4ADF-9A1D-7ECD6A5C1E68Q34273354-A14DA949-5426-4674-96D5-3F9868812C19Q35201574-FF395F3D-B48D-407D-8203-1E0A6AAC0A2AQ36323469-C640B535-1297-4AF5-B44E-3886324E2DA5Q36441521-8DA4507B-F11E-43CF-8197-5B114A8B8EC9Q37200660-4D3016D1-6C77-46A6-AEC8-E91E21F8BD6DQ37399446-45109542-566E-4CB9-887A-1AF3F51D83EFQ37458836-D21A160D-2ED3-46D1-999C-85A9C7CEA5ECQ37687997-87F0B59A-1AA6-4E26-AD8B-446F26D45872Q38052726-4DA9152A-D695-4B05-9BF8-895A56820805Q38070163-510D5732-D96C-4AAE-8271-9FC0C1A23A85Q38154911-0CE904F3-C6A6-4595-8193-F0509B6B0B38Q38154915-D3A8E2F8-359D-449D-96EF-51C96DCB3E9AQ38258243-22B46018-BC35-49C0-ACFC-09B44EEC3B5DQ38645670-CA9E4F9F-4835-47F3-A9E4-AF79F69E6DD6Q38731079-4D816605-A52C-4D1F-A5DE-1B392C653762Q38734042-B4E11644-9DB8-4F6C-9023-71E614FD1674Q38983579-EAFED62A-E842-442B-BB72-BB6560B27ADCQ39441964-08E84CD8-3DDF-4712-94FB-264EC7C1D17FQ46047040-D1117634-8C68-4671-B39B-C6A970775242Q46557713-80786FC7-0814-4102-A843-B9B764011327Q47760557-FE5BBB7F-E7E0-481F-942F-C08D6A79EEF8Q48057578-6C0E6F7F-9986-4F43-9A42-F52E56EEF8F0Q48655811-0A45527F-3DEB-462A-9D24-96D29DF5CA00Q51818173-E86CC3B8-12EA-4BB2-A3B9-65824D74B088Q52603826-132AAF0D-F7D7-48D6-9ABF-83AFDD08048DQ56898282-B5554821-DE3B-4364-810C-4AFE84ECF776
P2860
Influence of the CYP2D6*4 polymorphism on dose, switching and discontinuation of antidepressants.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Influence of the CYP2D6*4 poly ...... ntinuation of antidepressants.
@ast
Influence of the CYP2D6*4 poly ...... ntinuation of antidepressants.
@en
type
label
Influence of the CYP2D6*4 poly ...... ntinuation of antidepressants.
@ast
Influence of the CYP2D6*4 poly ...... ntinuation of antidepressants.
@en
prefLabel
Influence of the CYP2D6*4 poly ...... ntinuation of antidepressants.
@ast
Influence of the CYP2D6*4 poly ...... ntinuation of antidepressants.
@en
P2093
P2860
P1476
Influence of the CYP2D6*4 poly ...... ntinuation of antidepressants.
@en
P2093
Arnold G Vulto
Bruno H Ch Stricker
Loes E Visser
Monique J Bijl
Ron H N van Schaik
Teun van Gelder
P2860
P304
P356
10.1111/J.1365-2125.2007.03052.X
P407
P577
2007-12-07T00:00:00Z